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Abstract
Objectives Cardiac resynchronization therapy with a
biventricular pacemaker (CRT-P) is an effective treatment
for dyssynchronous heart failure (DHF). Adding an
implantable cardioverter defibrillator (CRT-D) may further
reduce the risk of sudden cardiac death (SCD). However, if
the majority of patients do not require shock therapy, the
cost-effectiveness ratio of CRT-D compared to CRT-P may
be high. The objective of this study was to systematically
review decision models evaluating the cost-effectiveness of
CRT-D for patients with DHF, compare the structure and
inputs of these models and identify the main factors
influencing the ICERs for CRT-D.
Methods A comprehensive search strategy of Medline
(Ovid), Embase (Ovid) and EconLit identified eight cost-
effectiveness models evaluating CRT-D against optimal
pharmacological therapy (OPT) and/or CRT-P.
Results The selected economic studies differed in terms
of model structure, treatment path, time horizons, and
sources of efficacy data. CRT-D was found cost-effective
when compared to OPT but its cost-effectiveness became
questionable when compared to CRT-P.
Conclusions Cost-effectiveness of CRT-D may increase
depending on improvement of all-cause mortality rates and
HF mortality rates in patients who receive CRT-D, costs of
the device, and battery life. In particular, future studies
need to investigate longer-term mortality rates and identify
CRT-P patients that will gain the most, in terms of life
expectancy, from being treated with a CRT-D.
Keywords Review  Cost-effectiveness  Cardiac
resynchronization therapy  Cardiac pacing 
Implantable cardioverter-defibrillator  Markov chains 
Models  Economic  Heart failure  Sudden cardiac death
JEL Classification C63  D61  I18  H43
Introduction
Cardiac resynchronization therapy (CRT) either via a
pacing device (CRT-P) or a pacemaker-defibrillator device
(CRT-D) is considered an effective treatment for patients
with congestive heart failure (CHF) and disturbances in
heart rhythm (arrhythmias) having New York Heart
Association (NYHA) class II, III and IV symptoms. Clin-
ical trials have shown that CRT may decrease the risk of
death from any cause for CHF patients by 24 % during a
mean follow-up time of 16 months (COMPANION study,
[1]) to 36 % during a mean follow-up of 29.4 months
(CARE-HF study [2]). The addition of an implantable car-
dioverter defibrillator to the resynchronization therapy
(CRT-D) can further reduce the risk of death from any
cause by more than 8 % (compared to CRT-P) [3], while
the risk of sudden death (SCD) can be reduced by 23 % [4–
6]. However, overall costs of CRT-D are high and it is
reported that about 25 to 35 % of the patients do not
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respond to CRT-P [7] while implantable cardioverter
defibrillators (ICDs) are not always needed to deliver the
therapy [5].
A number of published economic studies have looked at
the cost-effectiveness of the CRT-P and CRT-D devices for
patients with CHF. The studies have mostly shown that the
incremental cost-effectiveness ratios (ICERs) of CRT-D
compared to optimal pharmacological therapy (OPT) alone
or in combination with a CRT-P were too high due to large
numbers of patients not requiring shock therapy [8, 9]. The
main aim of the present study was to critically review
economic models evaluating CRT-D devices for patients
with heart failure (HF), compare the structure and inputs of
the cost-effectiveness models, and identify the main factors
influencing the cost-effectiveness of CRT-D devices in
comparison to OPT alone or in combination with CRT-P.
Methods
A systematic literature review was performed in order to
identify the existing full health-economic models indexed
in the main electronic databases such as Medline (Ovid),
Embase (Ovid) and EconLit. The search was limited to
articles published in the English language during the period
from January 2000 to December 2014. The search strategies
used a combination of Medical Subject Heading (MeSH)
and free-text terms grouped into four categories; disease
specific, device specific, economics and type of study. The
relevant MeSH terms included: ‘cardiac pacing, artificial’,
‘pacemaker, artificial’, ‘heart-assist devices’, ‘heart con-
duction system’, ‘defibrillators, implantable’, ‘costs and
cost analysis’, ‘economics, hospital’, ‘economics, medical’,
‘economics, nursing’, ‘economics, pharmaceutical’, ‘cost-
effectiveness’, ‘humans’. References of the identified arti-
cles were scrutinized for additional references. Search
strategies used to retrieve references from Medline (Ovid)
and Embase (Ovid) are given in Annex 1.
The selection of the studies was done through pre-de-
veloped inclusion criteria. Only model-based economic
evaluations (studies that included decision-tree models and
Markov chain models) of implantable CRT-D devices were
included. Trial-based economic evaluations were not eligi-
ble since most clinical studies have a short follow-up period
while benefits of the CRT-D devices are not fully observed
until the long term, and therefore we considered predictive
modelling as a more valid approach to capture all costs and
benefits of the therapy. All studies that were outside of the
review scope, i.e. economic evaluations alongside clinical
trials, reviews, meta-analyses, editorials, resource use
studies or studies on costs were excluded. The first author
performed the search and initial classification of the
retrieved articles. All the selected articles were read
independently by two reviewers (FT, ADIvA) and only
those fulfilling the selection criteria were included in the
review. Data extraction included: authors, year of publica-
tion, type of study and analysis, country of analysis, model
structure, sources of effectiveness data, sources of economic
data, sources of health state utilities, main comparators,
outcomes and perspective taken as well as the main findings.
Results
Search results
The search retrieved 1839 citations, which were reduced to
1420 after excluding for duplicates and for non-English
language citations. After screening titles and abstracts, 99
articles (Fig. 1), were further scrutinized to exclude papers
that fell outside the scope of the review. The remaining
references (15 studies) were scrutinized to include only
studies on: (1) HF patients with NYHA II, III or IV,
LVEF B 35 % [10], (2) treated with the CRT-D as a
comparator and (3) that included decision-tree models or
Markov chain models. The eight studies remaining [11–18]
included model-based economic evaluations (i.e., Markov
models and decision-tree models) of CRT-D implantations
and were included for further review.
Table 1 gives the general study characteristics of the
selected publications for this review. The selected studies
included economic models adapting perspectives of four
European health care systems (Belgium, Germany, Spain
and UK) [11–15, 17, 18] as well that of a middle income
country (Brazil) [16].
Modelling approaches
All models distinguish between a short-term (represented by
costs and consequences of the process of device implanta-
tion) and a long-term phase (represented by the costs and
consequences of the post implementation follow-up period).
The initial short-term implantation phase was generally
4 weeks while the long-term maintenance phase was the
lifetime of the patient (see Table 1). Four out of the eight
selected studies [13, 15–17] used a decision tree tomodel the
short-term phase while four of the other studies [11, 12, 14,
18] included this as an initial phase into the Markov cohort
models. All the selected studies [11–18] used a Markov
cohort model for the long-term maintenance period.
Paths in the short-term decision trees consisted of
combinations of four treatment strategies: (1) optimal
medical therapy (OPT), (2) CRT-P, (3) CRT-D and (4)
implantable cardioverter defibrillator (ICD). Bertoldi et al.
[16] linked successful implantation of the device (CRT-P,
CRT-D or ICD) to complications or no-complications after
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implantation, which then led to the long-term model.
Failure of implantation led to the long-term OPT strategy.
This was similar to Yao et al. [12] except that these
investigators allowed for up to three re-implantation
attempts.
Markov states used in the eight selected studies [11–18]
can be broadly classified into four categories: (1) the short-
term implantation period, (2) upgrading or switching
between different implantable devices (e.g. switching from
CRT-P to CRT-D), (3) the maintenance states after device
implantation or when on OPT therapy; and (4) the death
state. Table 2 gives a more detailed summary of these
Markov states.
As mentioned, four out of the eight delected studies [11,
12, 18] included the initial phase of the device imple-
mentation in the Markov model by adding the following
states: (1) surgical intervention for CRT implantation, (2)
hospitalisation because of complications after CRT
implantation and (3) death because of CRT implantation
(or any subsequent operation). The consequent mainte-
nance states usually referred to events like stable state
(while on CRT or OPT), hospitalisation due to lead dis-
placements or infections, hospitalisation due to HF wors-
ening and hospitalisation due to other causes (e.g. heart
transplant, CABG, ablation, etc).
All models allowed patients to move from one Markov
state to another. Death states were detailed in SCD, HF
death, or death from non-cardiac related (nCR) causes. In
Yao et al. [12] patients that remained alive in the next time
period could continue being in the same NYHA class or
move to higher or lower NYHA classes. Similarly, in
Bertoldi et al. [16] patients could move between NYHA
classes (but with only a NHYA class at a time).
Upgrading devices from CRT-P to CRT-D was allowed
in three of the selected studies [11, 15, 17]. In such cases
CRT-P patients could at any time experience arrhythmia
Total records identified (n=1839):
- Medline (Ovid)
- EMBASE (Ovid)
- EconLit
Level 1
Records screened for economic 
outcomes (n=1420)
Level 2
Records screened for including cardiac 
resynchronization therapy
(n=539)
Level 3
Records screened for including a CRT-
D comparator
(n=99)
Level 4
Records include CRT-ICD as a 
comparator.
(n=15)
Duplicated or non-English records 
dropped 
(n=419)
Records excluded as did not report on 
economic outcomes
(n=881)
Records excluded as the focus was not 
on cardiac resynchronization therapy
(n=440)
Records did not meet the inclusion 
criteria for including a CRT-D 
comparator
(n=84)*
Level 5
Records considered for the review
(n=8)
Records did not include a decision tree 
or Markov cohort chain model for HF 
patients with NYHA II, III or IV, and 
LVEF ≤ 35%
(n=7)
Fig. 1 The selection process *Reviews, editorials, resource use and
cost studies, as well as economic evaluations alongside a clinical trial
were excluded at this step. CRT-D, cardiac resynchronization therapy
device with the addition of an implantable cardioverter-defibrillator;
HF, heart failure; NYHA, New York Heart Association functional
classification; LVEF, left ventricular ejection fraction
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and thereafter upgrade to a CRT-D device. In addition to
the above states the model by Fox et al. [11] (which con-
sists of a synthesis of the existing models) allowed also for
device explanting or replacement of the CRT-D device
with a new one. Patients could also be switched to the OPT
arm or get an ICD alone but only when experiencing
arrhythmias or receiving a heart transplant (heart transplant
state was also allowed in Colquitt [18]).
Patient population
The population considered in the selected studies were
adults (aged 18 and over) eligible for CRT implantation.
Eligibility criteria in all the studies were largely associated
with the guidelines for CRT implantation in patients suf-
fering from heart failure. These guidelines recommend
implantation of a CRT device (with or without ICD) for
Table 2 Overview of the Markov states in the selected studies
Health state categories in the Markov
cohort models
Fox
et al.
[11]
Yao
et al.
[12]
Aidelsburger
et al. [13]
Bond
et al. [14]
Callejo
et al. [15]
Bertoldi
et al. [16]
Neyt
et al.
[17]
Colquitt
et al. [18]
Short-term states
CRT-P implantation (operation) H n.a. n.a. H H n.a. H H
Complications after CRT
implantation
H n.a. H H n.a. H
Death (CRT-P implantation or
subsequent operation)
H n.a. n.a. H H n.a. H H
Upgrading/switching state
Upgrading CRT-P to a CRT-D
(operation)
H n.a. H H H H
ICD implantation (operation) H n.a. n.a. n.a. n.a. n.a. H H
Maintenance states
Patient with CRT has no adverse
eventsa
H H H H H H H H
Patient receiving OPT has no adverse
eventsa
H H H H H H H H
Patient with ICD has no adverse
eventsa
H n.a. n.a. n.a. n.a. H H H
Hospitalization—CRT-related
infection
H H H H H H H
Hospitalization—ICD-related
infectionb
H n.a. n.a. n.a. H H
(Hospitalization)—lead failure/
displacement
H H H H H
HF hospitalisation H H H H H H
Hospitalisation—heart transplant H H H H
Hospitalisation—CABG H H
Hospitalisation—Radiofrequency
ablation
H H
Hospitalisation—PTCA/Stent H H
Maintenance of CRT (e.g.
device/battery change) (operation)
H H H
Long-term death states
Death from SDC H H H H H H H H
Death from HF H H H H H
Death from nCR causes H H H H
a This means that these events do not take place during the model cycle
b Yao et al. [12] include two additional states the Coronary Care Unit (CCU) and the intensive care unit (ICU)
SDC Sudden Cardiac Death, HF Heart failure, nCR non-cardiac-related, PTCA Percutaneous Transluminal Coronary Angioplasty, n.a. not
applicable
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patients who have left ventricular ejection fraction (LVEF)
B35 %, a QRS duration C120 ms, sinus rhythm, and fall
within NYHA functional class III or ambulatory class IV
heart failure [4, 10, 19, 20]. Most of the studies complied
with these criteria. Five out of the eight selected studies
[11, 12, 14, 15, 18] used clinical data from the Care-HF
trial, (a multicentre, international randomized trial com-
paring CRT-P to OPT) [2], while two other studies [13, 17]
used data from the COMPANION trial (also a multicentre,
international randomized trial comparing CRT-P to OPT
Table 3 Values of health state
utilities for the selected studies
Mean Utility 95 % CI Min–max values Source
Yao et al. [12] and Aidelsburger et al. [13]
NYHA class I 0.82 (0.78:0.85) [2]
NYHA class II 0.72 (0.69:0.75) [2]
NYHA class III 0.59 (0.55:0.63) [2]
NYHA class IV 0.51 (0.41:0.61) [2]
Fox et al. [11] and Bond et al. [14]
NYHA class I 0.93 (0.91:0.96) [8]
NYHA class II 0.78 (0.72:0.84) [8]
NYHA class III 0.61 (0.59:0.63) [27]
NYHA class IV 0.44 (0.42:0.46) [27]
Bertoldi et al. [16]
NYHA class I 0.90 (0.71:0.94) [28–30]
NYHA class II 0.83 (0.61:0.94) [28–30]
NYHA class III 0.74 (0.52:0.84) [28–30]
NYHA class IV 0.60 (0.42:0.74) [28–30]
Callejo et al. [15]
NYHA class I 0.69 (0.53; 0.85) [31]
NYHA class II 0.60 (0.46; 0.74) [31]
NYHA class III 0.49 (0.34; 0.64) [31]
NYHA class IV 0.35 (0.15; 0.55) [31]
Neyt et al. [17]a 0.78 (0.73:0.83)b [9]
Colquitt et al. [18]
NYHA class I 0.86 (0.85:0.86) [29]
NYHA class II 0.77 (0.76:0.78) [29]
NYHA class III 0.67 (0.73:0.77) [29]
NYHA class IV 0.53 (0.48:0.58)
a Neyt et al. [17] use only mean utility values for the overall sample
b 97.5 % confidence interval
Table 4 Incremental cost-effectiveness ratios (in euros per QALYs gained)a
CRT-P versus OPT CRT-D versus OPT CRT-D versus CRT-P CRT-D versus ICD
Fox et al. [11] €20,077 €28,372 €48,179 –
Yao et al. [12] €6763 €16,166 €42,986 –
Aidelsburger et al. [13] – €76,350 – –
Bond et al. [14] €19,865 – €47,662 –
Callejo et al. [15] €30,307 – €56,719 –
Bertoldi et al. [16] €11,808 – €63,343 €32,664
Neyt et al. [17] €9849 – €49,774 –
Colquitt et al. [18] €29,551b €29,889a €30,447a €29,135b
a Indexed for purchasing power parities for GDP [26] and in 2014 prices
b Corresponds to population II in Colquitt et al. [18], i.e., patients with heart failure as a result of LVSD and cardiac dyssynchrony despite
receiving OPT; Corresponds to population III in Colquitt et al. [18] i.e., group II plus patients at risk of SDC due to ventricular arrhythmias
despite receiving OPT)
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and CRT-D to OPT) [1]. Both trials used similar eligibility
criteria for the selection of patients [1, 2]. Bertoldi et al.
[16] used data from an outpatient clinic in a Brazilian
hospital but reported a similar target population. Colquitt
et al. [18] used data from the MADIT-CRT [21] and RAFT
[22] trials for the comparison of CRT-D with ICD arms.
Colquitt et al. [18] distinguished between three different
population groups. However, for consistency with the
populations of other studies, here we focus on the analysis
of group II (i.e., patients with heart failure as a result of left
ventricular systolic dysfunction (LVSD) and cardiac
dyssynchrony despite receiving OPT) [18].
Model comparators
Six [11, 12, 14–17] out of eight selected studies included
three comparators; CRT-P with OPT, CRT-D with OPT,
and OPT alone. One study [13] compared only cost-ef-
fectiveness of CRT-D against CRT-P. Colquitt et al. [18]
included also comparisons of ICD with OPT and CRT-D
(though this was done in a different patient population).
Model time horizon
Pharmacoeconomic guidelines agree that the time horizon
of a cost-effectiveness model should extend far enough in
the future to capture the major health and economic out-
comes, including both the intended and unintended effects
[23]. With treatment for heart failure, certain treatment
outcomes can be realized over a shorter period (like the
outcome of the surgical intervention) while others, such as
a possible effect on survival, can only be realized over a
long time horizon (extending to lifetime of the patient).
The duration of clinical trials testing the cardiac resyn-
chronization therapy in heart failure disease varies from
6 months [21, 24] to 12 months [25] or to a longer period
of 29 months [2]. In the selected modelling studies, patient
outcomes and costs were simulated over 20 years [16] or
over the complete lifetime of the patient [11, 12, 14, 15, 17,
18], except for one study [13] which applied a time horizon
of only 2 years after implantation (Table 1). This is con-
sidered rather a conservative approach, as the high costs of
implantation cannot be fully recovered within such a short
term. The authors justified their choice by explaining the
difficulties in the extrapolation of utilities, costs and tran-
sition probabilities beyond the 2-year follow-up of the
COMPANION trial [1].
Resource use and unit prices
Resource use and unit prices in the selected studies were
predominantly obtained from the health care systems of the
respective countries. All the eight selected studies [11–18]
employed a payer perspective. As such, they have included
costs of CRT-P, CRT-D and ICD devices, costs of device
implantation, lead replacement, heart failure hospitalisation
and follow-up costs while in a stable health state. The level
of detail varied substantially between the studies, and was
predominantly dependent on the structure of the short-term
or long-term models (see also above).
It should be noted that prices of devices differed
between studies reflecting also the market value of the
devices over time. Hence, earlier studies by Fox et al. and
Yao et al. [11, 12] estimated prices of the CRT-D devices
in the UK healthcare setting at respectively €19,196 and
€19,914 (converted into 2014 prices in euros using OECD
estimates of purchasing power parities (PPPs) for GDP [26]
while the most recent study from Colquitt et al. [18] esti-
mated this at only €13,170 (PPP adjusted and in 2014
prices).
Table 5 Incremental cost-effectiveness ratios (International € per LYs gained)a
CRT-P versus OPT CRT-D versus OPT CRT-D versus CRT-P CRT-D versus ICD
Fox et al. [11] – – – –
Yao et al. [12] €6291 €32,179 €32,179 –
Aidelsburger et al. [13] – €168,040 – –
Bond et al. [14] – – – –
Callejo et al. [15] €24,806 – €34,160 –
Bertoldi et al. [16] €22,088 – €46,890 €34,054
Neyt et al. [17] €11,256 – €38,781 –
Colquitt et al. [18] €31,060b €13,926b €7375b €21,411b
a Indexed for purchasing power parities for GDP [26] and in 2014 prices
b Corresponds to population II in Colquitt et al. [18], i.e., patients with heart failure as a result of LVSD and cardiac dyssynchrony despite
receiving OPT; Corresponds to population III in Colquitt et al. [18] i.e., population group II in (a) plus patients at risk of SDC due to ventricular
arrhythmias despite receiving OPT)
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Health state utilities
The primary outcomes were quality-adjusted life years
(QALYs) or life years (LYs). All the studies use the NYHA
Functional Classification to assign the quality of life (QoL)
scores for patients in each health state. Again, the only
exception here is the study by Aidelsburger et al. [13] that
also included hospitalisations as an outcome.
The calculation of QALYs in the selected studies was
based on utility values from NYHA classes (Table 3).
Seven out of eight studies [11–16, 18] distinguish between
utility values for each NYHA class. Neyt et al. [17] con-
sidered mean health utilities by treatment rather than by
NYHA class. They argued that this was preferred, given
the substantial variation of NYHA class utility estimates
between publications. In fact, health utility values used per
NYHA class do vary greatly between studies, as can be
seen from values in Table 3.
Cost-effectiveness results
ICERs for cost per QALY gained and cost per LY gained
are presented in Tables 4 and 5. After checking for trans-
ferability criteria [32, 33], all ICERs were converted in
2014 prices in euros using PPPs [26]. Seven out of the eight
selected studies [11, 12, 14–18] reported cost-effectiveness
results per QALY for CRT-P compared to OPT and for
CRT-D compared to CRT-P, four studies [11–13, 18] for
CRT-D compared to OPT, and two studies [16, 18] for
CRT-D compared to ICD (Table 4). Despite the differ-
ences in ICERs, results were consistent in showing that
CRT-P was mostly cost-effective in comparison to OPT
alone. However, results were less clear for ICERs of CRT-
D compared to OPT. In the study by Aidelsburger et al.
[13] this ICER was much higher than in other studies
(€76,350) which could relate to the time horizon of only
2 years in this study. In general, ICERs for CRT-D com-
pared to CRT-P were considerably higher than for CRT-D
compared to OPT. Hence, ICERs for CRT-D versus CRT-P
ranged from €42,986 to €63,343 while ICERs per QALY
for CRT-D versus OPT ranged from €16,166 to €29,889.
The only exception was the study from Colquitt et al. [18]
where both ICERs were comparable (€29,889 vs €30,447),
but these did not apply to the same population [18]. It
should be noted that most ICERs for CRT-D versus CRT-P
are well above what is considered cost-effective in most
countries (for instance the £20,000-£30,000 threshold
applied in the UK [34]—converted to €21,427-€32,139
PPP adjusted). Bertoldi et al. [16] suggested that CRT-D
therapy should not be systematically recommended for
CRT-P eligible patients, while it can be an option for ICD
eligible patients. Yao et al. [12] suggested that CRT-D was
not cost-effective, particularly for CRT-P patients with
poor life expectancy. Fox et al. [11] called for more
research to explore the added value of CRT-D over CRT-P
and for improving identification of non-responders among
patients in the CRT-D group.
Two studies [16, 18] reported ICERs for QALYs gained
for CRT-D compared to ICD. Both ICERs were compa-
rable, ranging from €29,135 to €32,664 (even though they
concern different populations). Colquitt et al. [18] found
such ICERs to be robust and influenced only from all-cause
mortality in the ICD-only arm and lifetime of CRT-D and
ICD devices [18].
Two of the selected studies [11, 14] did not report on
ICERs per LY (Table 5). As for the other studies, similar
trends held as in ICERs per QALY. The ICER for the com-
parison between CRT-D and OPT in the Aidelsburger et al.
study [13] appears to be much higher than others, while
ICERs for CRT-D against CRT-P remain constantly higher
than ICERs for CRT-D against OPT. Again the study from
Colquitt et al. [18] is an exception here, although these results
should be cautiously interpreted as the population inColquitt
et al. [18] is not the same as in other studies.
Uncertainty
All selected studies [11–18] reported univariate sensitivity
analysis on key variables. Key determinant variables were
battery longevity [12, 13, 16, 18], cost of the device [16,
18] as well as relative risk for mortality from HF (for CRT-
P vs OPT or CRT-D vs CRT-P) [14, 16, 18]. Decreasing
the cost of the CRT device by 50 % decreased the ICERs
by 23 % for CRT-D vs CRT-P or by 40 % for CRT-P vs
OPT [16]. The selected studies assumed a base case battery
life that varied from 5 [16] to 6.5 years [14, 15] for CRT-P
devices and from 5 [16, 17] to 5.5 years [14, 15] for CRT-
D. Yao et al. [12] assumed a base case battery life of
7 years for CRT-D. Increasing battery life by 40 %
decreased the ICERs by more than 20 % in Bertoldi et al.
[16] and by 29 % in Colquitt et al. [18]. The reduction of
mortality with CRT-D by 13.3 % decreased the ICER for
CRT-D vs CRT-P by 36 % [16] while the decrease in
relative risk for HF death in CRT-D patients by 20 %
decreased the ICER by 58 % [15]. Five studies reported
probabilistic sensitivity analyses [11, 12, 16–18], while one
study [13] stated to have performed a two-way sensitivity
analysis, but did not report the results. Four out of the eight
selected studies [11, 12, 17, 18] incorporated cost-effec-
tiveness acceptability curves (CEACs), which are used to
summarize the uncertainty in the cost-effectiveness esti-
mates. The CEACs in these four studies showed that, for a
willingness-to-pay (WTP) threshold between €27.000 and
€44.000 (PPP adjusted) per QALY, the probability of CRT-
D being cost-effective compared to OPT or CRT-P was
only 26–40 %.
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Discussion
The review of the 6 selected economic evaluation models
from January 2000 to December 2015 showed that CRT-P
devices for HF patients could be considered a cost-effec-
tive therapy, if compared to OPT. However, implanting a
CRT-D device instead of a CRT-P appeared much less
cost-effective. Sensitivity analysis showed that cost-effec-
tiveness of CRT-D over CRT-P depends on costs of device,
battery life and relative risk for HF death in CRT-P
patients. Most of the selected studies agreed that there is a
need for a better identification of patients that will have a
substantially improved life expectancy after implanting the
CRT-D [11, 14, 15, 17].
The review showed that incremental cost-effectiveness
ratios depend on characteristics of the models adopted by
the selected studies. We have identified some variability in
the decision models used by the selected studies. Such
variability was observed around a number of method-
ological domains and the main assumptions used. First, the
modelling approaches included both decision-trees and
Markov structures. In chronic diseases Markov models are
preferred over decision trees as the latter ones can get too
complex over a longer time span, if they should account for
switching between health states. Instead, Markov models
can be more flexible and able to incorporate a series of
transitions between health states over a number of discrete
time periods [35–37]. However, the combination of both
short-term decision trees and Markov structures in four of
the selected studies allowed the different treatment strate-
gies and various complications (associated with the
implantation period) to be captured in the model. In fact,
such a combination seems to be common practice in eco-
nomic models of CRT for HF [11] and it is very unlikely to
impact the ICERs.
We have also found that numbers of health states in
the Markov structures varied between the selected stud-
ies, especially regarding the hospitalisation states. It is
usually recommended that the number of states is kept as
small as possible given that estimations of deterministic
models using averages can cause statistical bias in
average outputs [40, 41]. However, there are no reasons
to believe that such differences could have been main
causes behind the differences in ICERs in our selected
models.
Other modelling differences in the selected studies
included treatment cross-overs, (i.e. upgrading from CRT-
P to CRT-D [11, 13–15, 17] or downgrading from CRT-D
to ICD [11]) and using utility values per NYHA class [11,
12, 14–16, 18] versus the mean utility over all NYHA
classes [17]. However, it is difficult to speculate on the
impact these differences may have had on the ICERs.
The assumptions on the HF mortality and the hospital-
isation rates of patients having a CRT-D as compared to
those staying on OPT or having CRT-P alone were con-
sidered important in accurately simulating real-life events.
All the selected studies in this review used data from
existing clinical trials [1, 2, 21] whose follow-up periods
were much lower than the time horizon chosen in the
studies. The incremental effectiveness of CRT-D after the
follow-up period of the trials was maintained constant over
time in all the selected studies [11–18]. This may have
potentially led to an overestimation of the incremental
effectiveness of CRT-D as it is likely that relative benefits
of CRT-D fade out as severity of HF increases.
The assumed battery life of the pulse-generating devices
was also shown to be an important determinant of the
uncertainty in the cost-effectiveness estimates. The service
time of the CRT-P and CRT-D devices is limited by the
battery life (as battery replacement alone is not feasible and
a surgical operation is needed for the replacement of the
entire unit) [18]. An assumption of longer intervals for
device replacement would make the CRT-D appear more
cost-effective than the comparators. We found that the
studies did not differ very much on this assumption, though
longer service times could potentially increase the cost-
effectiveness of CRT-D in the future.
Additional sources of variability were differences in
resource use and unit prices across the studies, differ-
ences in time horizons applied, and uncertainty around
the primary efficacy of data used in the models.
Resource use and unit prices may create difficulties in
comparison of the results across jurisdictions [38].
Therefore, any comparison of the results in this review
should be considered with caution. On the other hand, as
shown here, the costs of the CRT devices tended to
decrease over time even within the same country [11, 12,
18] and this can be a crucial factor in determining cost-
effectiveness in the future.
The time horizon applied is also important as the full
effects of CRT on patient survival can only be revealed
over a patient’s lifetime [39]. Aidelsburger et al. [13] had a
much shorter life horizon, which directly impacted the
ICERs of CRT-D in comparison with CRT-P. The uncer-
tainty around the efficacy data used in the models (derived
from different clinical trials or meta-analyses) hampers the
interpretation of results. There was only one head-to-head
comparison trial for CRT-P versus CRT-D [25]. However,
this trial supported only the advantages of CRT-P over
OPT and CRT-D over OPT. There is no broad consensus
on the advantages of CRT-D over CRT-P, even though a
meta-analysis showed some superiority of the former on
all-cause death rate and cardiac death after 1-year follow-
up [3]. Other studies pointed out that CRT-D may be
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especially beneficial to a particular group of patients, like
women, those with longer QRS duration, and smaller
baseline LV volumes [42]. This review noted that the
ICERs for CRT-D versus CRT-P are still above what most
countries are willing to pay for an additional QALY (e.g.
the £20,000-£30,000 per QALY threshold applied in the
UK [34]). It is sensible to believe that a better identification
of patients for whom this technology is beneficial would
reduce unavoidable costs by making CRT-D a more cost-
effective alternative.
Conclusions
The studies included in this review seem to converge
around the finding that while CRT-P and CRT-D can be
considered cost-effective if compared to OPT, cost-effec-
tiveness of CRT-D over CRT-P remains questionable.
There is no broad consensus of the relative effectiveness of
CRT-D over CRT-P, and therefore studies looking at the
all-cause death rate and HF death rate could prove to be
important in reducing the uncertainty around cost-effec-
tiveness results. In addition, given the high proportion of
eligible patients not responding to CRT [7] or not needing
the addition of an ICD [5], future studies need to better
identify CRT-P patients that will have a reasonable life
expectancy when treated with CRT-D. This would bring
down avoidable costs, and consequently improve cost-ef-
fectiveness of CRT-D over CRT-P.
Authors&contributions All authors contributed to the study design
and coordination. F.T. performed the literature review and led
development of the manuscript. A.D.I.vA contributed to manuscript
development. F.P. provided an overall direction and critically
reviewed the manuscript. All authors have read and approved the final
manuscript.
Funding This work was supported by the Center for Translational
Molecular Medicine and The Netherlands Heart Foundation under the
‘Biomarkers to predict cardiac failure, arrhythmias and success of
treatment’ (COHFAR) project.
Compliance with ethical standards
Conflict of interest None declared.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
Appendix: Search strategy for cost-effectiveness
studies
Medline (OvidSP) and Embase (OvidSP)
1. Cardiac pacing, artificial/
2. Pacemaker, artificial/
3. Heart-Assist Devices/
4. Heart Conduction System/
5. Defibrillators, implantable/
6. CRT-P.mp.
7. CRT-D.mp.
8. (CRT or ‘‘cardiac resynchron$ therap$’’).ti,ab.
9. (resynchroni$ation or cardiac resynchronization
therapy or biv).tw.
10. (biventricular adj2 (pacing or pacer or pacemaker or
device)).tw.
11. ((implantable cardioverter-defibrillator) or (im-
plantable cardioverter$ adj2 defibrillator$)).tw
12. (dual adj2 chamber adj2 (pacing or pacer or
pacemaker)).tw.
13. (antitachycardia adj2 (pacing or pacemaker or pacer
or device)).tw.
14. (implantable$ adj2 cardioverter and
defibrillator$).ti,ab,ot,hw.
15. or/1-14
16. ((arrhythmia$) or (tachycardia$) adj2 (ventricular or
fibrillation)). ti,ab,ot,hw.
17. (heart adj4 failure).mp.
18. (left adj2 ventricular adj2 function or
dysfunction).tw.
19. (ventricular adj2 tachycardia$).tw.
20. Dyssynchrony.tw.
21. or/16-20
22. economics/
23. exp ‘‘costs and cost analysis’’/
24. exp ‘‘economics, hospital’’/
25. economics, medical/
26. economics, nursing/
27. economics, pharmaceutical/
28. (economic$ or cost or costs or costly or costing or
price or prices or pricing or
pharmacoeconomic$).ti,ab.
29. (expenditure$ not energy).ti,ab.
30. value for money.ti,ab.
31. budget$.ti,ab.
32. or/22-31
33. ((energy or oxygen) adj cost).ti,ab.
34. (metabolic adj cost).ti,ab.
35. ((energy or oxygen) adj expenditure).ti,ab.
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36. or/33-35
37. 32 not 36
38. letter.pt.
39. editorial.pt.
40. historical article.pt.
41. or/38-40
42. 37 not 41
43. Animals/
44. Humans/
45. 43 not (43 and 44)
46. 42 not 45
47. (Markov adj5 model$).ti,ab,pt
48. (Cohort$ simulation).tw
49. (Cost-effectiveness) .ti,ab,pt
50. Cost-effectiveness/
51. (Cost adj2 utility).ti,ab,pt
52. (Cost adj2 benefit).ti,ab,pt
53. or/47-52
54. 15 or 21
55. 54 and 46
56. 55 and 53
57. Limit 56 to yr=2000-2014
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